Venrock
Biotech Investor · 6 portfolio companies
Portfolio
6
Combined Value
$12.6B
Focus Areas
18
Top Stage
Phase 2
Investment Focus
Portfolio Companies
| Company | Valuation |
|---|---|
| Xenon Pharmaceuticals | $5.2B |
| Apogee Therapeutics | $4.5B |
| Innoviva | $1.6B |
| MapLight Therapeutics | $796.8M |
| Evolus | $301.9M |
| Pliant Therapeutics | $79.9M |
Frequent Co-Investors
Public shareholders1 sharedPublic market investors1 sharedFairmount Funds Management LLC1 sharedArch Venture Partners1 sharedBaker Bros. Advisors1 sharedOther institutional public market investors1 sharedGlaxoSmithKline (royalty partner/shareholder)1 sharedInstitutional and public shareholders1 shared